Literature DB >> 32010567

Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI).

Hiren Mandaliya1,2, Mark Jones3, Christopher Oldmeadow2,3, Ina Ic Nordman1,2.   

Abstract

BACKGROUND: Currently, there is no single validated biomarker which can prognosticate survival in patients with stage IV non-small cell lung cancer (NSCLC). This study examines the prognostic significance of four biomarkers: neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI) in patients with stage IV NSCLC.
METHODS: This study aimed to establish the relationship between NLR, LMR, PLR, ALI and overall survival (OS) at baseline and post first cycle of treatment using Cox univariate PH models. We also studied these biomarkers in the elderly (age ≥70 years). Clinical data was sourced from Calvary Mater Newcastle between 2010 and 2015.
RESULTS: Baseline NLR, PLR, LMR and ALI showed strong association with OS. Five unit increase in NLR and PLR was associated with an 11% and 0.5% increase in the hazard of death respectively while 1 unit increase in ALI resulted in 4% increase in hazard of death. Five unit increase in LMR was associated with a 50% reduction in hazard of death. Post-treatment NLR and low ALI correlated with shorter OS but no statistically significant relationship could be demonstrated for PLR nor LMR. Similar prognostic trends were noted for elderly.
CONCLUSIONS: High NLR, high PLR, low LMR and low ALI at baseline are significantly associated with poor OS. High NLR and low ALI are significantly associated with poor OS post treatment. Findings are similar regardless of age. 2019 Translational Lung Cancer Research. All rights reserved.

Entities:  

Keywords:  Prognostic; biomarker; lung cancer

Year:  2019        PMID: 32010567      PMCID: PMC6976360          DOI: 10.21037/tlcr.2019.11.16

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  15 in total

1.  Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.

Authors:  Gui-Nan Lin; Jie-Wen Peng; Jian-jun Xiao; Dong-Ying Liu; Zhong-Jun Xia
Journal:  Med Oncol       Date:  2014-06-14       Impact factor: 3.064

Review 2.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

Review 3.  Cancer in Australia: Actual incidence data from 1982 to 2013 and mortality data from 1982 to 2014 with projections to 2017.

Authors: 
Journal:  Asia Pac J Clin Oncol       Date:  2017-09-20       Impact factor: 2.601

4.  Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer?

Authors:  Berna Akinci Ozyurek; Tugce Sahin Ozdemirel; Sertac Buyukyaylaci Ozden; Yurdanur Erdoğan; Ozlem Ozmen; Bekir Kaplan; Tugba Kaplan
Journal:  Clin Respir J       Date:  2018-02-09       Impact factor: 2.570

Review 5.  Greater risks of chemotherapy toxicity in elderly patients with cancer.

Authors:  Lazzaro Repetto
Journal:  J Support Oncol       Date:  2003 Nov-Dec

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer.

Authors:  S Cedrés; D Torrejon; A Martínez; P Martinez; A Navarro; E Zamora; N Mulet-Margalef; E Felip
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

8.  Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis.

Authors:  Xiao-Bin Gu; Tian Tian; Xiao-Jing Tian; Xiao-Jun Zhang
Journal:  Sci Rep       Date:  2015-07-24       Impact factor: 4.379

Review 9.  Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.

Authors:  Syed H Jafri; Runhua Shi; Glenn Mills
Journal:  BMC Cancer       Date:  2013-03-27       Impact factor: 4.430

10.  Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; W J Angerson; D J Dunlop
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more
  68 in total

1.  Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab.

Authors:  Wei-Xiang Qi; Yi Xiang; Shengguang Zhao; Jiayi Chen
Journal:  Cancer Immunol Immunother       Date:  2021-04-01       Impact factor: 6.968

2.  Prognostic Roles of Inflammation- and Nutrition-Based Indicators for Female Patients with Cancer.

Authors:  Ming Yang; Qi Zhang; Yizhong Ge; Meng Tang; Chunlei Hu; Ziwen Wang; Xi Zhang; Mengmeng Song; Guotian Ruan; Xiaowei Zhang; Tong Liu; Hailun Xie; Heyang Zhang; Kangping Zhang; Qinqin Li; Xiangrui Li; Xiaoyue Liu; Shiqi Lin; Hanping Shi
Journal:  J Inflamm Res       Date:  2022-06-17

3.  Relationship between lymphocyte to monocyte ratio and brain metastasis in non-smalll cell lung cancer patients.

Authors:  Yafeng Liu; Chunxiao Hu; Jing Wu; Jiawei Zhou; Wenyang Wang; Xueqin Wang; Jianqiang Guo; Qingsen Wang; Xin Zhang; Jun Xie; Yingru Xing; Xuansheng Ding; Dong Hu
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

4.  A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers.

Authors:  Changchun Lai; Chunning Zhang; Hualiang Lv; Hanqing Huang; Xia Ke; Chuchan Zhou; Hao Chen; Shulin Chen; Lei Zhou
Journal:  Cancer Med       Date:  2021-05-11       Impact factor: 4.452

Review 5.  Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.

Authors:  Mengke Niu; Ming Yi; Ning Li; Suxia Luo; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2021-03-02

6.  Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.

Authors:  Chunyan Zhou; Dong Duan; Shuang Liu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

7.  Combination of preoperative red cell distribution width and neutrophil to lymphocyte ratio as a prognostic marker for gastric cancer patients.

Authors:  Lei Fu; Qian Li; Qingxia Fan
Journal:  J Gastrointest Oncol       Date:  2021-06

8.  Prognostic value of the neutrophil-to-lymphocyte ratio in acute organophosphorus pesticide poisoning.

Authors:  Yuhang Mu; Boqi Hu; Nan Gao; Li Pang
Journal:  Open Life Sci       Date:  2021-07-15       Impact factor: 0.938

9.  The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor.

Authors:  Anna Cho; Helena Untersteiner; Fabian Fitschek; Farjad Khalaveh; Philip Pruckner; Noemi Pavo; Karl Rössler; Christian Dorfer; Brigitte Gatterbauer; Christoph Höller; Manuela Schmidinger; Josa M Frischer
Journal:  J Neurooncol       Date:  2021-06-20       Impact factor: 4.130

10.  Predictive value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and lymphocyte-to-monocyte ratio (LMR) in patients with non-small cell lung cancer after radical lung cancer surgery.

Authors:  Baoqian Zhai; Jia Chen; Jiacheng Wu; Lei Yang; Xiaoli Guo; Jingjing Shao; Hong Xu; Aiguo Shen
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.